Vunakizumab demonstrates superior efficacy over placebo in active psoriatic arthritis in phase 2 trial
Elevated FABP4 levels linked to higher risk of local postoperative complications following total joint arthroplasty
Nipocalimab plus certolizumab did not improve primary outcomes in active rheumatoid arthritis in the phase 2a DAISY-RA Study
Rituximab demonstrates significant real-world effectiveness and acceptable safety in Sjögren’s disease: Evidence from the PORTRESS registry
Anifrolumab demonstrates rapid and sustained disease control in real-world systemic lupus erythematosus study
RA flares assessed by FLARE-RA questionnaire linked to disease activity measures but not structural damage progression
Tight-control strategy with golimumab achieves high remission rates in early axial spondyloarthritis regardless of gut inflammation
Radiographic non-progression linked to greater low disease activity achievement in psoriatic arthritis patients on secukinumab
